{"title":"Fifty Years of Non-Adrenergic Inotropes in Heart Failure.","authors":"Piero Pollesello, Zoltán Papp","doi":"10.1097/FJC.0000000000001892","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001892","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Deubiquitinase OTUB1 attenuates pathological cardiac hypertrophy by activating the AMPK signaling pathway.","authors":"Liqin Zhuang, Jun Xiong, Zhijian Wu, Huihong Zeng, Yuanping Cao, Xia Yan, Yanqing Wu, Jinying Tong","doi":"10.1097/FJC.0000000000001890","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001890","url":null,"abstract":"<p><p>Cardiac hypertrophy, a response to pathological stimuli, eventually progresses to heart failure. Ovarian tumor-associated proteinase B1 (OTUB1), a deubiquitinase of the ovarian tumor (OUT) family, regulates inflammation, cell survival, and oxidative stress in various diseases, but its role in cardiac hypertrophy remains unclear. Here, we investigated OTUB1 expression, function, and mechanism in pathological cardiac hypertrophy. OTUB1 expression was significantly downregulated in human hypertrophic hearts, transverse aortic constriction (TAC)-induced mouse hypertrophic hearts, and phenylephrine-stimulated neonatal rat ventricular myocytes (NRVMs). OTUB1 knockout (KO) mice exhibited exacerbated TAC-induced cardiac hypertrophy, dysfunction, and fetal gene reactivation, whereas OTUB1 overexpression attenuated PE-induced cardiomyocyte enlargement. Mechanistically, OTUB1 directly bound to, deubiquitinated, and stabilized Sirt2, thereby promoting AMPK phosphorylation. Silencing Sirt2 abolished the anti-hypertrophic effects of OTUB1 and blocked AMPK activation. In conclusion, OTUB1 protects against pathological cardiac hypertrophy by stabilizing Sirt2 and activating the AMPK signaling pathway, suggesting that OTUB1 is a promising therapeutic target for hypertrophy-associated heart failure.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Silent Window: Detecting Duchenne Cardiomyopathy Before Ejection Fraction Decline.","authors":"Justin R Dalton, Frank J Raucci, Adolfo G Mauro","doi":"10.1097/FJC.0000000000001885","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001885","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlo Acierno, Damiano D'Ardes, Andrea Boccatonda, Davide Nilo, Alfredo Mauriello, Vincenzo Russo, Alfredo Caturano
{"title":"Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications.","authors":"Carlo Acierno, Damiano D'Ardes, Andrea Boccatonda, Davide Nilo, Alfredo Mauriello, Vincenzo Russo, Alfredo Caturano","doi":"10.1097/FJC.0000000000001887","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001887","url":null,"abstract":"<p><p>Lipoprotein(a) [Lp(a)] is a genetically determined apolipoprotein B-containing lipoprotein independently associated with atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Circulating Lp(a) concentrations are largely inherited, minimally responsive to lifestyle modification, and not adequately addressed by conventional lipid-lowering pharmacotherapy. Patients with established ASCVD continue to experience recurrent cardiovascular events despite intensive guideline-directed therapy, and this residual risk reflects mechanisms - including persistently elevated Lp(a) - that are not captured by standard low-density lipoprotein cholesterol (LDL-C) management. In this narrative review, current evidence on Lp(a) biology, genetics, and pathophysiology is integrated with a critical appraisal of contemporary management, the emerging Lp(a)-lowering pharmacological landscape, and unresolved clinical implementation challenges. Current management relies on once-in-adulthood Lp(a) measurement for cardiovascular risk stratification, aggressive optimization of modifiable risk factors, and, in highly selected patients, lipoprotein apheresis; no Lp(a)-specific pharmacotherapy is approved by any major regulatory agency. RNA-targeted therapies - antisense oligonucleotides and small interfering RNA agents - and an oral inhibitor of Lp(a) particle assembly have produced pharmacodynamic Lp(a) reductions of 80-95% or more in phase 2 randomized trials. However, topline results from the phase 3 Lp(a)HORIZON trial showed that pelacarsen, despite lowering Lp(a), did not reduce the primary composite cardiovascular endpoint. Full trial data are awaited, while four other phase 3 cardiovascular outcome trials - OCEAN(a)-Outcomes, ACCLAIM-Lp(a), MOVE-Lp(a), and OCEAN(a)-PreEvent - remain ongoing. Should positive outcome data emerge, clinical implementation will require regulatory approval, evidence-based patient selection, standardized treatment thresholds, and equitable access strategies across diverse populations.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Massimiliano Camilli, Michela Ortenzi, Ludovica Leo, Marcello Viscovo, Eugenio Galli, Priscilla Lamendola, Ludovica Amore, Stefan Hohaus, Simona Sica, Filippo Crea, Francesco Burzotta, Giorgio Minotti, Antonella Lombardo
{"title":"Rationale and Design of the CARdio-Tox Study: A Prospective Evaluation of Cardiovascular Toxicity in Patients Receiving Chimeric Antigen Receptor-T (CAR-T) Cell Therapy.","authors":"Massimiliano Camilli, Michela Ortenzi, Ludovica Leo, Marcello Viscovo, Eugenio Galli, Priscilla Lamendola, Ludovica Amore, Stefan Hohaus, Simona Sica, Filippo Crea, Francesco Burzotta, Giorgio Minotti, Antonella Lombardo","doi":"10.1097/FJC.0000000000001886","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001886","url":null,"abstract":"<p><p>Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum of manifestations, from paucysimptomatic and reversible effects to potentially fatal cardiovascular damage. The 2022 European Society of Cardiology (ESC) guidelines on cardio-oncology highlighted the need for systematic cardiovascular assessment in patients receiving CAR-T therapy, yet specific monitoring protocols are lacking at this point in time. The CARdio-Tox study was conceived to address this surveillance gap, testing the hypothesis that acute systemic inflammation, particularly mediated by high levels of interleukin (IL)-1 and IL-6 pathways, might represent the key determinant of early myocardial dysfunction. The primary endpoint of this protocol is to assess the incidence of acute CTR-cardiac dysfunction (CTRCD) occurring within 7 and 30 days after CAR-T cell infusion. Key secondary endpoints include the assessment of the relationship between CTRCD occurrence and CRS diagnosis and grade, as well as the association of inflammatory biomarkers increase with cardiac imaging and/or serum biomarker abnormalities. Data collection will continue over 30 days to assess middle and long-term cardiovascular toxicity. Despite its single-center design, the CARdio-Tox results might provide clinically relevant insights into early cardiovascular effects of CAR-T cell administration, identify key risk factors for CTR-CVT and support more tailored, pathophysiology-driven monitoring strategies in this rapidly evolving field.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sharmaine Thirunavukarasu, Denise T W Tiong, Maggie He, Arka Das, Heerajnarain Bulluck
{"title":"One Month Versus Three Months of Aspirin After Percutaneous Coronary Intervention: A Reconstructed Time-to-Event Analysis.","authors":"Sharmaine Thirunavukarasu, Denise T W Tiong, Maggie He, Arka Das, Heerajnarain Bulluck","doi":"10.1097/FJC.0000000000001882","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001882","url":null,"abstract":"<p><p>P2Y12-inhibitor monotherapy after abbreviated dual antiplatelet therapy (DAPT) reduces bleeding after percutaneous coronary intervention, but whether aspirin can be stopped after one month rather than three remains uncertain. We reconstructed time-to-event data from published Kaplan-Meier or cumulative-incidence curves of 11 randomised trials (37,443 patients) using the Guyot algorithm, grouped trials by aspirin-withdrawal timing, and analysed within-trial monotherapy-versus-continued-DAPT effects using stratified Cox regression and random-effects meta-analysis across 0 to 30, 30 to 90, and 90 to 360-day intervals. Reconstructed event totals matched published totals exactly for all 12 curves, and reconstructed hazard ratios agreed with published estimates to within 2.2%. Monotherapy approximately halved major or minor bleeding (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.44-0.59). One-month and three-month withdrawal produced comparable ischaemic-composite effects (risk ratio 0.88, CI 0.75-1.03, and 0.92, CI 0.74-1.15); these trials were not randomised against one another, so comparable estimates do not establish clinical equivalence. The only early excess arose with near-immediate withdrawal, driven entirely by NEO-MINDSET (0 to 30-day interval rate ratio 2.09, CI 1.33-3.28); excluding this trial left no ischaemic excess in the remaining trial. Myocardial infarction (HR 1.02, CI 0.82-1.28) and stent thrombosis (Peto odds ratio 1.19, CI 0.77-1.86) showed no overall excess. These hypothesis-generating findings, derived from reconstructed rather than true individual-participant data and from an indirect comparison across trials, suggest the relevant distinction may be immediate versus deferred aspirin withdrawal rather than one versus three months, though the early hazard rests on a single trial and requires independent replication.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zain Ul Abideen, Muhammad H Waseem, Areeba Shoaib, Tehreem Fatima, Muhammad Mukhlis, Nohela Rehman, Pawan K Thada, Ameer H Cheema
{"title":"Efficacy and Safety of Lorundrostat for Uncontrolled and Treatment-resistant Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Zain Ul Abideen, Muhammad H Waseem, Areeba Shoaib, Tehreem Fatima, Muhammad Mukhlis, Nohela Rehman, Pawan K Thada, Ameer H Cheema","doi":"10.1097/FJC.0000000000001850","DOIUrl":"10.1097/FJC.0000000000001850","url":null,"abstract":"<p><strong>Abstract: </strong>Uncontrolled hypertension remains a major contributor to cardiovascular morbidity and mortality. Lorundrostat directly reduces aldosterone synthesis and represents a targeted therapeutic strategy. The aim of this study was to evaluate the comparative efficacy and safety of lorundrostat among adults with uncontrolled or treatment-resistant hypertension. We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 guidelines and identified relevant randomized controlled trials from PubMed, ScienceDirect, and CENTRAL databases through August 2025. Data for various outcomes were extracted after computing the risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences (MDs) with 95% CIs for continuous outcomes. We included 3 randomized controlled trials, with 1165 patients receiving lorundrostat and 403 patients receiving placebo. The efficacy outcomes demonstrated a significant reduction in systolic blood pressure (MD: -8.00; 95% CI: -10.81 to -5.19; P < 0.00001) and diastolic blood pressure (DBP) (MD: -3.31; 95% CI: -5.56 to -1.07; P = 0.004) with lorundrostat. Regarding safety outcomes, lorundrostat reported a higher incidence of adverse events (RR: 1.47; 95% CI: 1.29 to 1.67; P < 0.00001), hyperkalemia (RR: 9.17; 95% CI: 2.24 to 37.44; P = 0.002), and symptomatic hypotension (RR: 2.97; 95% CI: 1.12 to 7.90; P = 0.03), whereas the incidence of serious adverse events (RR: 1.29; 95% CI: 0.33 to 5.03; P = 0.71) was comparable between the 2 groups. Lorundrostat effectively reduced blood pressure; however, its use was accompanied by increased adverse events, hyperkalemia, and symptomatic hypotension. Efficacy must therefore be weighed carefully against safety, taking into account the patients' baseline characteristics.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"269-276"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Myra Lewontin, Antonio Abbate, Todd C Villines, David Guarraia, Michael Ayers
{"title":"Aspirin in Primary Prevention: A Case for Selective Use.","authors":"Myra Lewontin, Antonio Abbate, Todd C Villines, David Guarraia, Michael Ayers","doi":"10.1097/FJC.0000000000001841","DOIUrl":"10.1097/FJC.0000000000001841","url":null,"abstract":"<p><strong>Abstract: </strong>Low-dose aspirin has a well-established role in secondary prevention of cardiovascular disease, but use in primary prevention remains uncommon due to limited evidence of benefit and risk of adverse effects such as bleeding. While benefit of aspirin in primary prevention may not outweigh risk in the general population, it may still be appropriate for particular groups in which benefit would be greater. Novel biomarkers for cardiovascular risk can help identify these groups. These include imaging markers such as coronary artery calcium scoring and carotid plaque assessment, and laboratory markers such as lipoprotein(a) and high-sensitivity C-reactive protein. Use of these biomarkers for more effective risk stratification can delineate groups of patients with greater potential benefit from aspirin and help guide risk-benefit conversations regarding primary prevention.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"263-268"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148329848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jacopo D'Andria Ursoleo, Giuseppe Biondi-Zoccai, George W Booz
{"title":"Quo Vadis Aspirin In Primary Prevention?","authors":"Jacopo D'Andria Ursoleo, Giuseppe Biondi-Zoccai, George W Booz","doi":"10.1097/FJC.0000000000001865","DOIUrl":"10.1097/FJC.0000000000001865","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"259-262"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148603344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}